Business
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and
About this update from Ars Pharmaceuticals, Inc.
[{"type":"text","content":"$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians More than 5,000 physicians have prescribed neffy to date, reinforcing the demand for a safe, effective, needle-free treatment for severe allergic reactions including anaphylaxis Conference call to be held today, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for the first quarter of 2025 and provided an update on the continued U.S. commercial launch of neffy® (epinephrine nasal spray), the first and only FDA-approved and European Commission approved needle-free epinephrine treatment for Type I allergic reactions, including anaphylaxis. First Quarter 2025 Financial Results Revenue: Total revenue for the first quarter of 2025 was $8.0 million, which was comprised of $7.8 million in net product revenue from neffy sales in the U.S. and $0.2 million in collaboration revenue from ALK-Abelló A/S (ALK).Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2025 were $3.0 million, which was primarily associated with continued clinical and development expenses for neffy.Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the first quarter of 2025 were $41.1 million, of which the significant majority were personnel-related and sales and marketing expenses associated with the commercialization of neffy. The company is committed to make a substantial investment in the launch of neffy to ensure short and long-term patient and physician awareness and market share.Net Loss: Net loss for the first quarter of 2025 was $33.9 million, or $0.35 per share.Cash Runway: As of March 31, 2025, ARS Pharma had cash, cash equivalents, and short-term investments of $275.7 million, with 98,129,804 shares of common stock outstanding. The company reiterates its guidance that its financial position is expected to support its operating plans for at least ...